Immunotherapy: combination regimens and new data on the significance of mutations - memoinOncology
Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care - ILCN.org (ILCN/WCLC)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 - ScienceDirect
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 - JTO Clinical and Research Reports
Immunotherapy: combination regimens and new data on the significance of mutations - memoinOncology
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 - ScienceDirect
Kaplan-Meier analysis of progression-free survival in the (A)... | Download Scientific Diagram
Kaplan-Meier analysis of progression-free survival in the (A)... | Download Scientific Diagram
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | NEJM
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo ...
Lancet Oncol 2016;17(11): Updated Results from KEYNOTE-021 Cohort G: A Randomized, Phase 2 Study of Pemetrexed and Carboplatin (PC) with or without. - ppt download
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials - Borghaei - 2020 - Cancer -
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 - ScienceDirect
KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease - ILCN.org (ILCN/WCLC)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 - ScienceDirect
AACR 2018: First-Line Management of Advanced NSCLC Enters New Era - ILCN.org (ILCN/WCLC)
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407 - ScienceDirect
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | NEJM
Efficacy - MSD Connect
KEYNOTE-024 and KEYNOTE-042 - First-line Monotherapy for Advanced NSCLC Clinical Trial Results
Stephen V Liu, MD on Twitter: "KEYNOTE 189 set our standard. Important to keep providing long term updates. Thanks and congrats to authors @delvysra @EnriquetaFelip @ManuelDomine @MartinReck2 @MichaelBoyer1 @cpiedoc @marinagarassino #LCSM https://t.co ...
First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study - Amrane - 2020 - Cancer Medicine - Wiley Online Library
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 - Journal of Thoracic Oncology
Immunotherapy: the emerging paradigm of cure - memoinOncology
